9,27 $
2,22 %gestern
Nasdaq, 21. Februar, 22:13 Uhr
ISIN
US03969K1088
Symbol
ARQT
Berichte
Sektor
Industrie

Arcutis Biotherapeutics Inc Aktie News

Neutral
GlobeNewsWire
6 Tage alt
Arcutis today announced that it will report its fourth quarter and full year financial results and provide a business update on Tuesday, February 27, 2024.
Neutral
GlobeNewsWire
15 Tage alt
WESTLAKE VILLAGE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 33,750 restricted stock units of Arcutis' common stock to five newly hired employees. These awards were approved by the Compensation ...
Positiv
InvestorPlace
17 Tage alt
The biotech sector is one of my favorite sectors since it is not only constantly growing and with companies that are always doing wonderful research, products, and solutions, but it is also a sector that is constantly innovating and contributing to the health of the human being. If you want to participate as an investor in this sector and take advantage of companies that have great growth oppor...
Neutral
GlobeNewsWire
22 Tage alt
WESTLAKE VILLAGE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference.
Negativ
Seeking Alpha
22 Tage alt
Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
Neutral
GlobeNewsWire
24 Tage alt
Novel steroid-free topical foam effectively controls seborrheic dermatitis Once-daily ZORYVE® (roflumilast) topical foam, 0.3%, is approved to treat seborrheic dermatitis in individuals 9 years of age and older WESTLAKE VILLAGE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful i...
Neutral
GlobeNewsWire
etwa ein Monat alt
First drug approved for seborrheic dermatitis with a new mechanism of action in over two decades available in pharmacies this week Effective, safe, and very well-tolerated steroid-free foam provides rapid disease clearance and significant reduction in itch Seborrheic dermatitis affects more than 10 million people in the United States Management will host conference call on Monday, January 22 at...
Neutral
GlobeNewsWire
etwa ein Monat alt
New subgroup analysis from STRATUM study shows that individuals with an inadequate response, contraindication, or intolerance to steroids were 3.5 times more likely to achieve IGA Success with ZORYVE foam than an identical vehicle ZORYVE foam provided rapid and significant improvement in quality of life scores in patients 17 years and older Data presented at the 2024 Winter Clinical Dermatology...
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen